After eight years, Macro Polo has ceased operations as the Paulson Institute will focus its independent research on supporting its programs as it continues to diversify its scope.
We appreciate the community that has grown around Macro Polo and the fruitful engagement we’ve had with our legion of smart and sharp audience. You’ve pushed us to deliver even more original work and innovative products. Our body of work speaks for itself, and we hope it will have a long shelf life – that was the intent from MP’s inception.
MP’s website is now archived and no new work will be published henceforth on this site. Please visit www.paulsoninstitute.org for future research and policy work on a range of global issues.
Thank you all for the support over the years, it has been a privilege to have had a home at the Paulson Institute and to have built it the way we did.
- Team Macro Polo
As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Jiangsu Hengrui Medicine develops, manufactures, and supplies pharmaceuticals, including anti-cancer and cardiovascular drugs and surgical anesthesia. One of its anesthesia products has gained FDA approval for the US market. The company has also set up research and testing facilities in the United States.
Sun Piaoyang
Lianyungang, Jiangsu
(0518) 8122.0678
600276@hrs.com.cn
Hengrui USA LLC 2005 Eastpark Blvd Cranbury, NJ 08512 Ph: 609.619.3156
The company has a subsidiary in New Jersey, which, by the end of 2016, had added a clinical center and an R&D center for about $1.2 million.
In November 2014, the company established its European subsidiary in Willich, Germany with registered capital of $1 million.